✦ LIBER ✦

Immunotherapy for metastatic prostate cancer

✍ Scribed by Charles G. Drake

Book ID: 116956124
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 113 KB
Volume: 26
Category: Article
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2007.03.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOCUS on FOCIS: Combined chemo-immunothe

FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer

✍ Daniela Rožková; Hana Tišerová; Jitka Fučíková; Jan Lašt'ovička; Michal Podrazil 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 674 KB

Development of sipuleucel-T: Autologous

Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

✍ Robert B. Sims 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 432 KB

Phase 1/2 dose-escalation study of a GM-

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

✍ Celestia S. Higano; John M. Corman; David C. Smith; Arthur S. Centeno; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## BACKGROUND This open‐label, multicenter, dose‐escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone‐refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate‐carcinoma cell line

Immunotherapy for prostate cancer

✍ Lawrence Fong; Eric J Small 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Immunotherapy for prostate cancer

✍ Lawrence Fong; Eric J. Small 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 177 KB

Immunotherapy for prostate cancer

✍ Lawrence Fong; Eric J. Small 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 123 KB